Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
INVOKANA helped lower A1C in adult patients with T2D in need of glycemic control 2 Adjusted mean change from baseline in a monotherapy study 2 In patients with an eGFR 60 mL/min/1.73 m 2 needing additional glycemic control, the dose can be increased to 300 mg once daily
It holds water in the intestinal lumen, counteracting the increased water absorption that comes with extended transit time
Preliminary real-world data from Milliman suggests that while increased GLP-1 adherence may lower the medical cost of care for certain chronic conditions, these offsets do not yet fully recover the high cost of the medications themselves
Clinical trial data shows diarrhea rates of 19-23% across doses, with nausea remaining the predominant side effect at 24-31%
In the brain, they are most highly expressed in the hypothalamus, specifically the ventromedial nucleus and arcuate nucleus
Orforglipron was associated with pulse increases that were consistent, in magnitude and time course, with those observed with other GLP-1 receptor agonists
US$ 23.83
US$ 20.50
US$ 26.03
